What Seegene Technologies does

Seegene Technologies is the US operating subsidiary of Seegene, Inc., a Seoul-headquartered molecular diagnostics company founded in 2000 and listed on KOSDAQ since 2010 under ticker KQ096530. The company develops proprietary multiplex real-time PCR technologies—DPO (Dual Priming Oligonucleotide), TOCE (Tagging Oligonucleotide Cleavage Extension), and MuDT (the world's first real-time PCR providing individual Ct values for multiple targets in a single channel without melt-curve analysis)—enabling simultaneous detection of up to 14 pathogens in a single reaction tube with quantitative results. Its product portfolio spans IVDR-certified Allplex assay panels for respiratory, gastrointestinal, STI, HPV, and antimicrobial resistance testing; Novaplex research-use assays for emerging pathogens including mpox; automation instruments (STARlet-AIOS, NIMBUS, and the fully unattended CURECA platform with modular CPS, PAS, and CEFA units); and the SG STATS analytical software layer.

The company's commercial model has shifted decisively toward the SG OneSystem technology-sharing platform, under which Seegene establishes jointly-controlled NewCo entities with leading national diagnostic companies—Hylabs in Israel (March 2023) and Werfen in Spain (May 2025)—granting them access to assay design, automation, validation, and AI-enabled development capabilities in exchange for localized manufacturing, distribution, and revenue participation. The SGDDS (Seegene Digitalized Development System) integrates Microsoft Azure OpenAI, Microsoft Fabric, and related services to automate reagent development and syndromic data analytics. Revenue is generated through technology licensing and royalties on NewCo commercialization, sale of IVDR assays outside the USA, and hardware sales of automation platforms. End-customers include hospital and clinical laboratories, government health agencies, and the NewCo partners themselves; the firm has supplied more than 340 million COVID-19 tests across 100+ countries and operates the Open Innovation Program jointly with Springer Nature. The US entity was established in Irvine, California in June 2025 as the beachhead for the technology-sharing model in the US market.

Name

Seegene Technologies

Legal name

Seegene, Inc.

Website

https://seegenetech.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Seegene Technologies is the US operating arm of Seegene, Inc., a Korean molecular diagnostics company that develops proprietary multiplex PCR assays, automation systems, and an AI-enabled development platform, serving clinical laboratories and national diagnostic partners worldwide through its SG OneSystem technology-sharing joint-venture model.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industry

Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels) (HLAHAOAJ)

Keywords

• Molecular diagnostics
• Multiplex PCR assays
• Automated testing systems
• Diagnostic reagents
• Syndromic PCR technology

Headquarters

HQ city

Walnut Creek

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Technology Licensing and NewCo Partnerships: Seegene shares its advanced diagnostic and data analysis technologies (syndromic real-time PCR and SGDDS) with leading companies partnered in each country through joint venture NewCos. Partners develop, manufacture, and distribute localized diagnostic products.
2. Diagnostic Reagent Sales: Sale of multiplex PCR assay products including IVDR assays for respiratory infections, gastrointestinal infections, STIs, HPV, and antimicrobial resistance. Products include Allplex brand assays sold globally.
3. Automated Testing Systems: Sale and distribution of automated molecular diagnostic testing systems including STARlet-AIOS, NIMBUS, and CURECA platforms for laboratories of various sizes.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Seegene Technologies develops and manufactures multiplex PCR molecular diagnostic assays (under brands such as Allplex and Novaplex) and automated testing systems (STARlet-AIOS, NIMBUS, CURECA) for clinical laboratories and healthcare providers. The company operates the SG OneSystem technology-sharing model, partnering with national diagnostic companies through NewCo joint ventures to develop, manufacture, and commercialize localized syndromic PCR products covering respiratory infections, gastrointestinal infections, sexually transmitted infections, HPV, and antimicrobial resistance.

Product overview

Seegene Technologies offers a comprehensive molecular diagnostics ecosystem centered on syndromic real-time PCR technology. The portfolio includes the SG OneSystem™ technology-sharing platform and SGDDS automated development system, supported by automation instruments (STARlet-AIOS™, NIMBUS, CURECA™) and core technologies (DPO™, TOCE™, MuDT™). The product line spans IVDR assay panels for respiratory infections (RP), gastrointestinal infections (GI), sexually transmitted infections (STI), HPV, and antimicrobial resistance (AMR), alongside specialized instruments (CPS, PAS, CEFA) and analytical tools (SG STATS). The company positions itself as a total PCR solution provider enabling simultaneous detection of up to 14 pathogens in a single tube.

Differentiator

Problem solved

Functional benefit

Brands

• Allplex: High-multiplex real-time PCR assay products for various infections including respiratory, gastrointestinal, STI, HPV, and antimicrobial resistance testing
• CURECA
• DPO
• TOCE
• MuDT
• STARlet-AIOS
• Seegene NIMBUS
• SG STATS
• SGDDS
• Novaplex

Products and services

• Allplex HPV HR Detection Real-time PCR assay designed to test for 14 high-risk HPV types, including types 16 and 18, in a single tube. Intended for cervical cancer prevention and follow-up management in clinical laboratories and screening programs.
• Allplex HPV28 Detection Real-time PCR assay designed to test for 28 HPV types (19 high-risk and 9 low-risk) in two tubes, providing individual genotypes and Ct values in one test for comprehensive cervical cancer screening and HPV genotyping.
• Novaplex MPXV Assay (RUO) Research-use-only PCR assay designed to detect mpox virus (MPXV), developed in 2022 using Seegene's SGDDS system for early mpox detection capability.
• Novaplex MPXV/OPXV plus Assay (RUO) Research-use-only PCR assay designed to detect MPXV Clade I (higher transmission/mortality) with specific confirmation, OPXV, and MPXV Clade II, meeting WHO target product profiles for mpox detection.
• Novaplex HSV-1&2/VZV/MPXV Assay (RUO) Research-use-only multiplex PCR assay designed to detect four viruses simultaneously: MPXV, herpes simplex virus types 1 and 2, and varicella-zoster virus (VZV).
• STARlet-AIOS Fully automated molecular diagnostic testing system that streamlines the entire PCR process from nucleic acid extraction to result analysis, featuring a modular design that integrates existing instruments for clinical laboratories.
• Seegene NIMBUS Automated testing system providing automation solutions tailored to the size and throughput needs of various testing laboratories.
• CURECA Seegene's fully automated molecular diagnostics platform designed to automate the entire PCR workflow including pre-treatment across diverse specimen types (stool, urine, blood, sputum) via its modular CPS, PAS, and CEFA subsystems, enabling fully unattended PCR automation.
• SG OneSystem Technology-Sharing Platform Seegene's technology-sharing platform through which partner companies in each country gain access to Seegene's assay design, automation, and validation capabilities to develop, license, manufacture, and distribute localized syndromic PCR diagnostic products in their markets.
• SGDDS (Seegene Digitalized Development System) Seegene's automated diagnostic reagent development system that integrates Microsoft Azure AI services to streamline assay design, validation, and regulatory submission workflows for syndromic PCR products.

Quantifiable outcome

• Simultaneous detection of 14 pathogens in a single reaction tube with quantitative information
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and major.

• WerfencoreStrategic or Co-development Partner · 1 May 2025Partnership agreement to co-establish Werfen-Seegene NewCo in Spain as strategic hub in Europe. Werfen is worldwide leader in specialized diagnostics. NewCo will develop products for infectious diseases including antimicrobial resistance testing, viral load testing, STI detection, and emerging diseases. Expected to secure CE-IVDR approval and expand into European and global markets.
• UK Health Security Agency (UKHSA)majorStrategic or Co-development Partner · 1 October 2024Prof. Dame Jenny Harries, Chief Executive of UKHSA, attended Seegene's Partner Executive Roundtable and visited Seegene headquarters in Korea to discuss pandemic response achievements and technology-sharing initiatives.
• Springer NaturecoreStrategic or Co-development Partner · 1 May 2024Strategic alliance to foster collaboration with researchers across various disease fields using Seegene's PCR diagnostic technology. Includes expansion of Open Innovation Program to Nature Awards MDx Impact Grants. Springer Nature promotes the program to global scientific community and oversees project submissions and evaluations.
• MicrosoftcoreTechnology or Integration · 1 January 2024Strategic collaboration to integrate Microsoft Azure AI solutions into Seegene's automated diagnostic reagent development system (SGDDS). Includes Azure OpenAI Service, Azure Trusted Research Environment, Microsoft Fabric analytics platform, and Copilot for Microsoft 365. Aims to empower global companies in the technology-sharing initiative with streamlined product development and AI-powered data analysis.
• International Vaccine Institute (IVI)majorStrategic or Co-development Partner · 1 January 2024MOU to utilize Seegene's HPV diagnostic reagents for Global HPV Burden Study testing approximately 50,000 people across eight Asian and African countries over five years. Study measures prevalence of 28 HPV types in women aged 9-50 to establish future cervical cancer vaccination policies. Supported by Bill & Melinda Gates Foundation.
• Hy Laboratories Ltd (Hylabs)coreStrategic or Co-development Partner · 1 March 2023First One System global partnership agreement with leading Israeli diagnostic company. Hylabs contributes five decades of leadership in molecular and microbiology diagnostics. Partnership enables localization of Seegene's syndromic PCR technologies to address local healthcare needs in Israel.

Scale indicators6 records

Recent moves16 records

Expansion highlights5 records

Direct peers

• Qiagen: Qiagen's QIAstat-Dx syndromic panels and sample-prep technologies directly compete with Seegene's multiplex PCR menus, and Qiagen also operates a partnered/OTG distribution model in several regions analogous to Seegene's NewCos.
• BioFire Diagnostics (bioMérieux): BioFire's FilmArray panels (respiratory, GI, meningitis/encephalitis, blood culture identification) are the benchmark syndromic multiplex molecular diagnostics system, competing head-to-head with Seegene's Allplex offerings in the same hospital and reference lab customers.
• DiaSorin (Luminex): DiaSorin's acquisition of Luminex brought the xTAG and xMAP multiplex molecular platforms used for respiratory, GI and STI syndromic panels, competing with Seegene's Allplex assays.
• Hologic: Hologic's Panther system with Aptima and Panther Fusion assays competes with Seegene's molecular diagnostics in women's health (HPV/STI) and hospital molecular testing.
• Cepheid (Danaher): Cepheid's GeneXpert system is a leading automated real-time PCR platform with Xpert syndromic panels (respiratory, GI, STI, AMR) overlapping directly with Seegene's reagent and instrument value proposition.

Others

• Werfen: Werfen is both a Seegene partner (newly forming the Spain NewCo JV in 2025) and a specialized-diagnostics incumbent with hemostasis, acute care and autoimmunity lines; inclusion is justified because the JV relationship makes them comparable in specialized IVD.

Broad incumbents

• Roche Diagnostics: Roche operates cobas and the GenMark ePlex syndromic molecular platform (post GenMark acquisition), giving it a broad IVD portfolio overlapping with Seegene's syndromic multiplex PCR positioning.
• Becton, Dickinson and Company (BD): BD's MAX System and broader microbiology/molecular diagnostics portfolio competes with Seegene's syndromic PCR in hospital labs, and BD's scale in clinical instrumentation makes it a cross-capability incumbent.
• QuidelOrtho: QuidelOrtho's Sofia and Savanna rapid molecular platforms, plus its broad IVD catalog, overlap with Seegene's syndromic infectious-disease testing menu and customer base.
• Abbott Diagnostics: Abbott's m2000 and Alinity m molecular systems offer PCR-based infectious disease and STI testing at scale, putting it in the same hospital and reference-lab RFPs that Seegene targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SeegeneTech
• Facebookfacebook.com/SeegeneTech

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seegene Technologies